Rosalind1 min read
OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems.
By Manuel UthThe Decoder

Read the full story
Originally published by The Decoder on Oct 21, 2026.
Comments
Sign in to join the discussion.